AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
LSE:AZN
Price:
10 914 GBX
0.48%
Market Closed
Updated:
Apr 19, 2024
AstraZeneca PLC
Capital Expenditures
Last
Value
3-Years CAGR
5-Years CAGR
|
AstraZeneca PLC
Capital Expenditures Peer Comparison
Comparables:
GSK
VRNA
INDV
HIK
DPH
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Capital Expenditures
$-3.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-6%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Capital Expenditures
£-2.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Capital Expenditures
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Capital Expenditures
$-53m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Capital Expenditures
$-204m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Capital Expenditures
£-30.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
See Also
What is AstraZeneca PLC's Capital Expenditures?
Capital Expenditures
-3.8B
USD
-3.8B
USD
Based on the financial report for Dec 31, 2023, AstraZeneca PLC's Capital Expenditures amounts to -3.8B USD.
What is AstraZeneca PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-6%
-6%
Over the last year, the Capital Expenditures growth was -47%. The average annual Capital Expenditures growth rates for AstraZeneca PLC have been -13% over the past three years , -22% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
